#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16792	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2092	796.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1733	1733	T	914	T,C,G	855,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16792	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2092	796.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1467	1467	C	965	C,T	907,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30294	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3798	795.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1751	1751	A	1008	A	965	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30294	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3798	795.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2385	2385	C	967	C	903	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30294	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3798	795.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2459	2459	A	948	A	902	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30294	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3798	795.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3011	3011	C	975	C,T	922,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2458	folP	855	855	100.0	folP.l15.c4.ctg.1	1501	162.8	1	SNP	p	R229S	1	.	.	685	687	AGC	1023	1025	AGC	267;267;267	A;G;C	257;257;253	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6304	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3394	184.9	1	SNP	p	S91F	1	.	.	271	273	TTC	635	637	TTC	228;226;228	T;T,C;C,T	218;214,2;216,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6304	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3394	184.9	1	SNP	p	G95N	0	.	.	283	285	GGC	647	649	GGC	211;209;210	G;G,A;C	197;192,2;196	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6304	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3394	184.9	1	SNP	p	D95G	1	.	.	283	285	GGC	647	649	GGC	211;209;210	G;G,A;C	197;192,2;196	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1966	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1338	145.8	1	SNP	p	G45D	0	.	.	133	135	GGC	583	585	GGC	255;254;259	G;G;C	237;236;245	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1026	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1064	95.8	0	.	n	.	0	A197.	DEL	197	197	A	611	611	A	205	A	198	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5666	parC	2304	2304	99.83	parC.l15.c30.ctg.1	2878	195.8	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1576	1578	GCA	217;214;213	G;C;A	200;196;195	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5666	parC	2304	2304	99.83	parC.l15.c30.ctg.1	2878	195.8	1	SNP	p	D86N	0	.	.	256	258	GAC	529	531	GAC	207;204;206	G;A;C	199;190;197	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5666	parC	2304	2304	99.83	parC.l15.c30.ctg.1	2878	195.8	1	SNP	p	R87I	0	.	.	259	261	CGT	532	534	CGT	207;209;211	C;G;T	200;202;203	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5666	parC	2304	2304	99.83	parC.l15.c30.ctg.1	2878	195.8	1	SNP	p	S87R	1	.	.	259	261	CGT	532	534	CGT	207;209;211	C;G;T	200;202;203	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5666	parC	2304	2304	99.83	parC.l15.c30.ctg.1	2878	195.8	1	SNP	p	R87W	0	.	.	259	261	CGT	532	534	CGT	207;209;211	C;G;T	200;202;203	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5666	parC	2304	2304	99.83	parC.l15.c30.ctg.1	2878	195.8	1	SNP	p	S88P	0	.	.	262	264	TCC	535	537	TCC	211;212;214	T;C;C	202;202;205	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4922	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2575	190.2	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1328	1330	TGC	239;235;237	T;G;C	227;220;222	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4922	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2575	190.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1538	1540	GGC	232;228;228	G;G,T;C	216;209,1;212	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	4492	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2487	179.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1328	1330	GCA	253;254;255	G;C;A	230;221;232	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4492	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2487	179.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1331	1333	ATC	252;249;251	A;T;C	231;228;229	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4492	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2487	179.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1343	1345	GTG	240;238;238	G;T;G	224;222;221	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4492	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2487	179.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1343	1345	GTG	240;238;238	G;T;G	224;222;221	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4492	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2487	179.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1847	1849	ACC	195;196;196	A;C;C	186;186;191	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4492	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2487	179.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1901	1903	GCG	185;186;188	G;C;G	166;151;157	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4492	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2487	179.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1901	1903	GCG	185;186;188	G;C;G	166;151;157	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4492	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2487	179.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2024	2026	GGC	206;204;204	G;G;C	196;192;195	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4492	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2487	179.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2033	2035	GGC	192;191;189	G;G;C	181;178;174	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4492	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2487	179.7	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2051	2053	TCG	179;185;185	T,G;C;G	122,10;152;144	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6470	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3216	200.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1660	1662	CCG	231;230;228	C;C;G	211;210;202	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2556	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1649	153.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	491	491	C	194	C	180	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3156	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1475	211.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	397	399	GAA	262;262;266	G;A;A	247;247;251	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3156	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1475	211.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	685	687	GAT	251;251;255	G,A;A;T	235,1;235;239	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3156	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1475	211.9	0	.	p	.	0	M141I	NONSYN	421	423	ATG	706	708	ATA	269;273;274	A;T;A,G	256;259;258,2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3156	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1475	211.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	808	810	TCA	271;268;268	T;C;A	249;250;252	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3156	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1475	211.9	0	.	p	.	0	F215T	NONSYN	643	645	TTT	928	930	ACT	259;260;260	A;C;T	243;247;247	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3156	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1475	211.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	937	939	GTG	254;253;252	G;T;G	243;243;239	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3156	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1475	211.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1267	1269	GCA	233;234;234	G;C,A;A	222;219,1;220	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3156	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1475	211.9	1	SNP	p	G120K	1	.	.	358	360	AAG	643	645	AAG	239;238;231	A;A;G	228;227;221	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3156	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1475	211.9	1	SNP	p	D121N	0	.	.	361	363	GAC	646	648	GAC	231;230;231	G,A;A;C	218,1;216;220	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3156	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1475	211.9	1	SNP	p	A121D	1	.	.	361	363	GAC	646	648	GAC	231;230;231	G,A;A;C	218,1;216;220	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12044	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	4860	247.0	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2040	2042	AAT	228;225;224	A;A;T	215;210;211	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1256	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	946	131.3	1	SNP	p	V57M	1	.	.	169	171	ATG	502	504	ATG	272;273;274	A;T;G	255;256;254	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
